Business
Practice ManagementMalpractice ConsultHealth Law & Policy
Media
Case-Based Peer PerspectivesInvestigator Perspectives Medical World NewsPodcastsUrology Medical PerspectivesUTv VideosPeer ExchangeSpecial ReportVirtual Tumor BoardInsightsMedcastPeers & Perspectives
Conferences
Conference ListingConference Previews Conference Recaps
Publications
Urology Times JournalEditorial Advisory BoardUrologists in Cancer CareSupplements and Featured PublicationsClinical Forums Recaps
More
CME/CE
Resources
Begin Your Journey: Tackling BurnoutSponsored MediaLive EventsInteractive ToolsJob BoardPartnersSponsored ResourcesTreatment Landscape Evolutions

Subscribe

  • Business
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Benign Conditions
  • Benign Prostatic Hyperplasia
  • Bladder Cancer
  • Female Urology
  • Genitourinary Cancers
  • Genomic Testing
  • Hormone Therapy
  • Kidney Cancer
  • Kidney Stones
    • Challenging Anatomy
  • Men's Health
  • Next-Generation Imaging
  • OAB and Incontinence
    • Voiding Dysfunction
  • Pediatrics
  • Prostate Cancer
    • Controveries in Urologic Cancer
    • Drug Therapy
  • Sexual Dysfunction
  • UTUC
  • Urologic Surgery
    • Cosmetic Surgery
Spotlight -
Peer Exchange|
Peers and Perspectives|
Case-Based Peer Perspectives|
Urology Times Journal
Advertisement

Parth Patel, MD

Advertisement

Articles by Parth Patel, MD

RFBSIP - stock.adobe.com

The case for transperineal prostate biopsy vs. the transrectal approach

ByParth Patel, MD,Alex Belshoff, MD, PhD,Gopal Gupta, MD
February 3rd 2020

Reduced infection rate may drive increased use of the transperineal approach.

Advertisement

Latest Updated Articles

  • RFBSIP - stock.adobe.com
    The case for transperineal prostate biopsy vs. the transrectal approach

    Published: February 3rd 2020 | Updated:



Advertisement
Advertisement

Trending on Urology Times

1

Choosing salvage therapy after prostate cancer focal ablation

2

Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC

3

SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort

4

CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC

5

SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do not sell my Personnal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us